摘要
目的探讨氨氯地平与特拉唑嗪联合应用治疗中老年男性原发性高血压患者的安全性。方法2005年8月～2006年2月在安徽省安庆市及其周边地区,采用随机开放平行前瞻性实验,开展了氨氯地平联合特拉唑嗪治疗中老年男性原发性高血压的研究。本文选择完成4w随访的研究对象508例,分析氨氯地平与特拉唑嗪联合用药治疗高血压的安全性。结果①联合用药组研究对象的心率,治疗前后分别为(68.9±7.7)次/分、(67.7±6.9)次/分,差异无统计学意义。②联合用药组对血糖、血脂、血钠、血钾、及肝肾功能均无显著性影响。③4w治疗期间,特拉唑嗪、氨氯地平、联合用药组不良事件的发生率分别为4.1%,12.3%,13.2%,差异有统计学意义;各组均未见体位性低血压的发生。结论氨氯地平和特拉唑嗪联合应用治疗高血压,对患者的心率、血糖和血脂代谢无不良影响;耐受性较好,未见明显的不良反应;通过对药物剂量的控制,各组均未见体位性低血压的发生。
Objective To evaluate the safety of combination therapy with amlodipine and terazosin in middle aged and old male patients with essential hypertension. Methods Randomized, prospective, parallel study was carried out in middle aged and old male patients with essential hypertension in Anqing between August 2005 and February 2006. In this article, 508 patients were chosen to appraise safety of the combination therapy. Results ①After 4 weeks, the heart rate of combination group changed from 68.9 ±7.7 to 67.7 ± 6.9. There was no significant difference before and after treatment. ②The combination group didn＇t affect the levels of blood glucose, lipid, electrolyte and the function of kidney and liver. ③As regards tolerability, adverse experiences were observed in 4.1% , 12.3 % , and 13.2 % of patients, respectively. Orthostatic hypertension did not happen in three groups during treatment. Con- clusions The combination of amlodipine and Terazosin have no influence on the levels of blood glucose, lipid and the function of kidney and liver. Moreover, the combination was tolerated as well as its components. Through the adjustment of drug dosage, orthostatic hypotension did not happen in three groups during treatment.
出处
《中华疾病控制杂志》
CAS
2008年第4期350-353,共4页
Chinese Journal of Disease Control & Prevention
关键词
高血压
抗高血压药
药物流行病学
Hypertension
Antihypertensive agents
Pharmacoepidemiology
